Drugs.com - New Drug Approvals

Mirum’s Livmarli Now FDA Approved in Tablet Formulation

FOSTER CITY, Calif.--(BUSINESS WIRE) April 14, 2025 -- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of Livmarli (maralixibat) for the treatment of...

May 12, 2025 - 10:14
 0
FOSTER CITY, Calif.--(BUSINESS WIRE) April 14, 2025 -- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of Livmarli (maralixibat) for the treatment of...
Read More

Tags:

Previous Article

Neurelis Announces FDA Approval for Immediate Use Seizure Medication Valtoco (di...

Next Article

FDA Grants Interchangeable Designation to Yuflyma (adalimumab-aaty), Celltrion's...

Related Posts

FDA Approves Mezofy (aripiprazole) Oral Film for the Treatment of Schizophrenia

FDA Approves Mezofy (aripiprazole) Oral Film for the Tr...

May 12, 2025  0

FDA Approves Tremfya (guselkumab) for Adult Patients wi...

May 12, 2025  0

Arcutis’ Zoryve (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older

Arcutis’ Zoryve (roflumilast) Topical Foam 0.3% Approve...

May 27, 2025  0